Why are iron tablet side effects worse with gastritis?

In a gastritis-affected stomach, the mucosal layer that normally buffers iron's Fenton reaction chemistry is thinned and the EGFR/ERK repair pathway is already suppressed by active inflammation. Iron ions reach the epithelial surface with less buffering, the oxidative damage is more severe, and the recovery between doses is slower. H. pylori adds a second independent NF-kB activation source, compounding the inflammatory state further.

Can iron tablets trigger a gastritis flare?

Yes. Iron's Fenton reaction generates reactive oxygen species that activate NF-kB — the same inflammatory transcription factor that H. pylori activates in gastritis. In a patient with active gastritis, this additive NF-kB activation can trigger or worsen a flare. The mucosal surface that is already inflamed responds more intensely to iron's chemical insult.

Can I take iron tablets if I have gastritis?

Yes — but the approach matters. Switching to ferrous bisglycinate substantially reduces the Fenton reaction rate. Taking iron with food reduces mucosal contact. Adding mucosal support (quercetin to inhibit NF-kB, glabridin to activate EGFR/ERK repair) addresses the compounding damage mechanism. If H. pylori is the cause of gastritis, treating it first significantly improves iron tolerability.

Does H. pylori make iron tablet side effects worse?

Yes — through two simultaneous mechanisms. First, H. pylori degrades the gastric mucus layer, removing the buffer between iron ions and the epithelial surface. Second, H. pylori already activates NF-kB continuously. Iron's oxidative stress adds a second NF-kB source on top of a system already running at maximum inflammatory capacity. The side effects compound additively.

Should I treat H. pylori before taking iron tablets?

If H. pylori is known or suspected, treating it before or alongside iron supplementation significantly improves tolerability. H. pylori also impairs iron absorption through multiple mechanisms — reducing gastric acid secretion, causing chronic blood loss, and competing for iron at the mucosal surface. Treating H. pylori addresses both the iron side effect problem and the iron deficiency problem simultaneously.

Why Are Iron Tablet Side Effects Worse If You Have Gastritis?

62%

of tested Indians with gut symptoms were H. pylori positive

Many are also iron-deficient due to H. pylori-impaired absorption — prescribed iron with a lining already damaged by the same infection. TumGard India Gut Health Report 2026, n=20,363.

Two problems that make each other worse

Iron deficiency and gastritis are not coincidentally linked. H. pylori — the bacterial infection responsible for the majority of chronic gastritis in India — directly impairs iron absorption by reducing gastric acid secretion, causing inflammation that disrupts the intestinal lining, and competing for iron at the mucosal surface.

The result is a clinical trap: the patient needs iron supplementation because H. pylori has caused iron deficiency — but the same infection has damaged the stomach lining in a way that makes iron supplementation significantly more painful and poorly tolerated.

The clinical trap in India

Standard prescribing gives patients iron without investigating the stomach lining first. 62% of symptomatic tested Indians carry H. pylori. Many of these patients are also iron-deficient. They receive iron with a lining already compromised by the bacteria causing both problems — and are not told that treating H. pylori would improve both their iron deficiency and their iron tolerability simultaneously.

What gastritis does to the stomach lining

In a healthy stomach, a thick gel of mucus secreted continuously by goblet cells coats the gastric epithelium and acts as a physical and chemical barrier between the stomach's contents and its wall. Gastritis disrupts this. Whether caused by H. pylori infection, prolonged NSAID use, or autoimmune processes, gastritis involves persistent inflammation of the gastric mucosa.

Over time, this inflammation erodes the epithelial layer, reduces goblet cell function, thins the protective mucus, and leaves the underlying epithelium increasingly exposed. This thinned, compromised lining is what iron encounters when a tablet is swallowed.

Why iron causes more damage on a gastritis-affected lining

Iron's mechanism of gastric irritation is oxidative. When ferrous sulphate dissolves, free iron ions undergo the Fenton reaction — generating reactive oxygen species that attack and damage the gastric epithelium. In a healthy stomach, the mucosal layer absorbs a significant portion of this oxidative insult before it reaches the epithelial cells. In a gastritis-affected stomach, that buffer is reduced. Iron ions make earlier and more direct contact with an already-inflamed and thinned epithelial surface.

The gastric mucosa in active gastritis has a reduced capacity to buffer chemical insults. In patients with H. pylori-associated mucosal damage, the protective mucus layer is actively degraded by bacterial virulence factors — leaving the epithelium more exposed to subsequent irritants, including iron salts.

Adapted from Laine L et al. · Gastroenterology · 2008 · PMID 18424695

H. pylori makes both problems worse simultaneously

H. pylori sits at the centre of this problem. It contributes to iron deficiency through several distinct mechanisms: reduced gastric acid (lowering ferrous iron conversion), chronic blood loss from gastric erosions, and lactoferrin competition for iron at the mucosal surface.

At the same time, H. pylori activates NF-kB continuously through its CagA virulence protein and lipopolysaccharide — driving the inflammatory cascade that thins the mucosa and suppresses EGFR/ERK repair. When iron's oxidative stress adds a second NF-kB activation source, the signals compound. The gastric inflammatory state is more severe than either source would produce alone.

H. pylori impairs iron absorption

Reduces gastric acid (lowering Fe³⁺→Fe²⁺ conversion), causes chronic mucosal blood loss, and competes for iron at the mucosal surface. The patient becomes iron-deficient.

Problem 1

Iron supplementation is prescribed

The correct clinical response to iron deficiency. But the stomach receiving iron is already damaged by the bacteria causing the deficiency.

Standard response

Iron's Fenton reaction hits damaged mucosa

Less mucosal buffering, more direct contact with the epithelial surface. Hydroxyl radicals cause more severe oxidative damage than they would on a healthy lining.

Compounding problem

Two simultaneous NF-kB sources

H. pylori activates NF-kB via CagA and LPS. Iron's ROS activates NF-kB via oxidative stress. Both drive the same inflammatory cascade — additively. The EGFR/ERK repair pathway is suppressed by both simultaneously.

The mechanism gap

What actually helps in this situation

The most complete approach addresses all three components of the problem:

Three-part approach

1. Switch to ferrous bisglycinate — the chelation reduces free iron availability and slows the Fenton reaction rate, producing substantially less oxidative damage on the already-compromised surface.

2. Investigate and treat H. pylori — an H. pylori breath test or stool antigen test is inexpensive and definitive. Treating H. pylori both improves iron absorption and removes the primary driver of mucosal damage that compounds iron's side effects.

3. Support mucosal repair — quercetin inhibits NF-kB (addressing both H. pylori's and iron's inflammatory activation), glabridin activates EGFR/ERK repair. This is the mechanism gap antacids don't fill.

References

Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Establishes how active mucosal inflammation reduces the stomach's capacity to buffer chemical insults, and the role of EGFR/ERK in repair.
Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Defines H. pylori's NF-kB activation mechanism and its suppression of mucosal repair — the primary reason H. pylori compounds iron-related gastric damage.
Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of 62% H. pylori positivity in symptomatic Indians who underwent endoscopy (n=1,111 sub-cohort of 20,363).

How our data compares

The 62% H. pylori rate is from TumGard's endoscopy sub-cohort — a symptomatic, help-seeking population. The overlap between iron-deficiency anaemia and H. pylori infection is clinically established in Indian gastroenterology literature, though precise co-prevalence data for the Indian population is limited. The clinical inference — that many iron-supplementing patients have undiagnosed H. pylori — is mechanistically supported by H. pylori's known effects on iron absorption.